Clinical trials: Hepatic Malignancies
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer Metastatic
E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research
Evaluation of patient acceptance and characterization of response behaviour for web-based compared with respective paperbacked patient reported outcomes.
- Trial name
- NCT03132506
- Testing
- patient-reported-outcomes
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- University Hospital Tuebingen
Neoplasm Metastases, Melanoma
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
Background: Cancers in other parts of the body often spread to the liver, developing tumors which in many instances cannot be removed with surgery.
- Conditions
- Neoplasm Metastases, Melanoma, Colorectal Neoplasms
- Trial name
- NCT01336985
- Testing
- Irinotecan, Chemoembolization, Drug-Eluting Beads
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatic Impairment
Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
This will be a Phase I, multicentre, single-dose, non-randomized, open-label, parallel-group study to examine the PK, safety, and tolerability of camizestrant 75 mg in post-menopausal female participants with moderate or severe…
- Trial name
- NCT05790304
- Testing
- Camizestrant
- Where
- 4 sites in United States, Bulgaria and 1 more
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Biliary Tract Cancer
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
This Phase II clinical trial is to study the effectiveness and safety of continuous hepatic arterial infusion (HAI) of Oxaliplatin and Fluorouracil in Patients with Unresectable Biliary tract carcinomas, and to explore a better…
- Trial name
- NCT01572324
- Testing
- Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University
Gastrointestinal Cancer (Esophagus, Gastric, Pancreatic, Hepatic, Colorectal and Anal), Lung Cancer
Evolution of Corporeal Composition in the PeriOperative Period
Denutrition and Obesity are risk factors for perioperative surgical complications. In patient with cancer, incidence of denutrition is markedly increased.
- Trial name
- ECCOP (NCT02143869)
- Testing
- Bioelectrical Impedance Analysis
- Where
- France
- Volunteers
- 374 people
- Sponsor
- Hôpital Européen Marseille
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
This multicenter retrospective study evaluated consecutive patients with large HCC and PVTT who received lenvatinib plus DEB-TACE with/without FOLFOX-HAIC between July 2019 and June 2021.
- Trial name
- NCT06265883
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most frequent primary tumour of the liver and is the third cause of cancer-related mortality worldwide.
- Trial name
- NCT02928627
- Testing
- Analysis of microRNA expression
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Stage IV
- Trial name
- ALERT-HCC (NCT05992220)
- Testing
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Asan Medical Center
Colorectal Neoplasms, Neoplasms
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors are often treated using a hepatic artery infusion (HAI) pump.
- Conditions
- Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma
- Trial name
- NCT07715903
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma.
- Trial name
- NCT06710223
- Testing
- SD-101, Cryotherapy, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Hepatic Cancer, Hepatocellular Carcinoma
Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy
How to accurately and safely evaluate regional liver function before hepatectomy remains an important unsolved problem in the surgical management of hepatocellular carcinoma (HCC).
- Conditions
- Hepatic Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07704203
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepatic Neoplasms
Does a Minimally Invasive Approach to Liver Resection Improve Postoperative Outcomes?
A retrospective cohort study was conducted using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database to identify adult patients who underwent liver resection between 2022 and 2023.
- Trial name
- NCT07169877
- Where
- United States
- Volunteers
- 9,411 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
This phase IIb trial tests the effect of HRX215 in treating patients with colorectal cancer that has spread from where it first started to the liver (liver metastasis) after undergoing a portal vein embolization (PVE).
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07612007
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of…
- Trial name
- NCT05407519
- Testing
- Tislelizumab + Sitravatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Provincial Hospital
Advanced Malignancies
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.
- Trial name
- NCT04831944
- Testing
- parsaclisib
- Where
- 5 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Hepatocellular Carcinoma
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world and causes death of about 600000~1000000 people each year.
- Trial name
- SOON (NCT01997957)
- Testing
- S-1
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
Hepatocellular Carcinoma
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick," to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Trial name
- NCT00054951
- Testing
- MTC-DOX for Injection
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- FeRx
Hepatocellular Carcinoma (HCC)
TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion
This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with…
- Trial name
- NCT07075562
- Testing
- Bevacizumab Arterial Perfusion plus TACE, Conventional Therapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Hospital of Hebei Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.